Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma

[1]  Michael Frankfurter,et al.  Cancer Principles Practice Of Oncology , 2016 .

[2]  M. Dimopoulos,et al.  International Myeloma Working Group recommendations for global myeloma care , 2014, Leukemia.

[3]  S. Rajkumar,et al.  The current status of minimal residual disease assessment in myeloma , 2014, Leukemia.

[4]  R. Kyle,et al.  An overview of the progress in the treatment of multiple myeloma , 2014, Expert review of hematology.

[5]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[6]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[7]  J. Shah,et al.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) , 2014, Leukemia.

[8]  F. Prósper,et al.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.

[9]  S. Rajkumar,et al.  IV. Initial treatment of multiple myeloma , 2013, Hematological oncology.

[10]  K. Anderson.  Therapeutic advances in relapsed or refractory multiple myeloma. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  N. Munshi,et al.  New Strategies in the Treatment of Multiple Myeloma , 2013, Clinical Cancer Research.

[12]  Gareth J. Morgan,et al.  A gene expression signature for high-risk multiple myeloma , 2012, Leukemia.

[13]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[14]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[15]  Hartmut Goldschmidt,et al.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. , 2011, Blood.

[16]  J. Shaughnessy,et al.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. , 2011, Blood.

[17]  Stefan Michiels,et al.  Multidimensionality of microarrays: Statistical challenges and (im)possible solutions , 2011, Molecular oncology.

[18]  T. Rème,et al.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines , 2011, Haematologica.

[19]  Cheng Li,et al.  A Survey of Classification Techniques for Microarray Data Analysis , 2011, Handbook of Statistical Bioinformatics.

[20]  Paul J. Kennedy,et al.  The curse of dimensionality: a blessing to personalized medicine. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[22]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[23]  P. Sonneveld,et al.  Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. , 2010, Blood.

[24]  P. L. Bergsagel,et al.  Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. , 2010, Blood.

[25]  B. Ghadimi,et al.  Cancer gene profiling for response prediction. , 2010, Methods in molecular biology.

[26]  M. Feith,et al.  Microarray-Based Response Prediction in Esophageal Adenocarcinoma , 2009, Clinical Cancer Research.

[27]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Nevins,et al.  Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Kyle,et al.  Treatment of multiple myeloma: a comprehensive review. , 2009, Clinical lymphoma & myeloma.

[30]  D. Esseltine,et al.  Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma , 2007, British journal of haematology.

[31]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Van Waes,et al.  The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas. , 2008, Biomarkers in medicine.

[33]  Mark D. Robinson,et al.  FIRMA: a method for detection of alternative splicing from exon array data , 2008, Bioinform..

[34]  J. Berenson,et al.  Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up , 2008, Annals of Hematology.

[35]  Koichi Nagasaki,et al.  Presidential symposium : Individualized diagnosis for tailored treatment of breast cancer Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer , 2008 .

[36]  John D. Shaughnessy,et al.  High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. , 2008, Blood.

[37]  J. Minna,et al.  Tumor mRNA expression profiles predict responses to chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[39]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[40]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[41]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[42]  David R Williams,et al.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.

[43]  A. Nobel,et al.  Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer , 2006, Molecular Cancer Therapeutics.

[44]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[45]  T. Yeatman,et al.  Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand? , 2006, Current opinion in oncology.

[46]  Jason McCoy,et al.  Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Fonseca,et al.  Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination. , 2005 .

[48]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Charles Auffray,et al.  Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Venables.  Aberrant and Alternative Splicing in Cancer , 2004, Cancer Research.

[51]  Andrew J. Wilson,et al.  Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. , 2003, Cancer research.

[52]  D. Black.  Mechanisms of alternative pre-messenger RNA splicing. , 2003, Annual review of biochemistry.

[53]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[54]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[57]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[58]  A I Pick,et al.  THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.

[59]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.